PHOTO CREDIT: Mayo Clinic

Biomedical Research News

  • 2021 Gerstner Sloan Kettering Chairman’s Prize Honors Research That Paves Way for New Cell-Based Therapies to Treat Autoimmune Diseases and Inflammation
    September 23, 2021

    Zhongmin Wang, a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2021 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Louis V. Gerstner, Jr. for whom the school is named. This year’s Chairman’s Prize, in the amount of $2,000, shines a light on Mr. Wang’s winning submission, which was published last month in Nature Immunology. Mr. Wang and his coauthors specifically designed mouse models for the project, which demonstrated that regulatory T (Treg) cells are fully functional under conditions of established inflammation and are capable of reversing, in addition to preventing, fatal autoimmunity. The results pave the way for the development of Treg cell-based therapies for a broad spectrum of autoimmune diseases and inflammatory disorders that raise the risk of cancer. “I am honored that the prize committee recognized the outstanding quality and potential impact of this research,” says Mr. Wang, who is conducting his dissertation studies in the laboratory of his thesis mentor, Alexander Rudensky, Chair of the Immunology Program at Memorial Sloan Kettering and senior author of the study.

    Read more at mskcc.org
  • Mayo Clinic Announces 2021 Gerstner Family Career Development Awardees

    Moritz Binder M.D., a physician-scientist in Mayo Clinic's divisions of Hematology and Oncology, and Satsuki Yamada, M.D., Ph.D., a physician-scientist in the division of Cardiovascular Diseases, are recipients of the 2021 Gerstner Family Career Development Awards. Dr. Binder is investigating mutation-specific therapeutic targets for chronic myelomonocytic leukemia, a cancer that starts in blood-forming cells of the bone marrow and invades the blood, and Dr. Satsuki is working to develop a targeted regenerative biotherapy to restore cardiac function in individuals who have suffered a myocardial infarction, also known as a heart attack. These competitive awards are presented annually by Mayo Clinic Center for Individualized Medicine to researchers conducting innovative investigations to predict, prevent, treat and cure disease using individualized medicine approaches. The Gerstner Family Career Development Awards is a benefactor-sponsored initiative that seeks to promote a specialized workforce for individualized medicine discovery, translation and application. Made possible by a grant from the Louis V. Gerstner, Jr. Fund at Vanguard Charitable, the award provides important seed money for early-stage investigators interested in launching a career in individualized medicine.

    Read more at mayoclinic.org
  • Could regenerative medicine relieve neck, back pain?

    Mayo Clinic is looking to regenerative medicine as a potential long-term solution for degenerative disk disease that has for years eluded medical science. Millions of people in the U.S. are afflicted with chronic neck and back pain that often comes after years of wear and tear on the spine. Current treatments provide only temporary relief for this common disorder, and finding a cure has been a great challenge for researchers. Wenchun Qu, M.D., Ph.D., a physiatrist and pain specialist at Mayo Clinic in Florida, and director of Regenerative Pain Medicine at the Center for Regenerative Medicine, hypothesizes that therapeutic answers to degenerative disk disease are hidden in mesenchymal stem cells. Dr. Qu's hypothesis is that mesenchymal stem cells could provide a new option for reducing inflammation, relieving pain and restoring spinal disks. He is applying his research to a regenerative medicine service he began at Mayo Clinic in Rochester and has now introduced at Mayo Clinic in Florida. In addition to this work, Dr. Qu is leading other regenerative medicine research to investigate the safety, feasibility and effectiveness of using bone marrow-derived mesenchymal stem cells to treat spine osteoarthritis with support from Gerstner Philanthropies.

    Read more at mayoclinic.org
  • MSK Recognizes 2021 Gerstner Sloan Kettering (GSK) Graduates During Virtual Commencement

    During a virtual commencement ceremony on Wednesday, May 19, 2021, at 3:00 pm et, Memorial Sloan Kettering Cancer Center (MSK) recognized seven Gerstner Sloan Kettering (GSK) 2021 graduates and honor Joan Argetsinger Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry at Yale School of Medicine and a Howard Hughes Medical Institute Investigator, with the 2021 Honorary Degree and the Memorial Sloan Kettering Medal for Outstanding Contributions to Biomedical Research. Established in 2004 with a landmark gift from Louis V. Gerstner, Jr., member of the MSK Boards of Trustees and Governing Trustees and chairman of the board of GSK, GSK admitted its first class in the summer of 2006. The school offers the next generation of biomedical scientists an intensive PhD program that trains them to investigate and attack cancer through the twin lenses of basic research and real-life clinical challenges.

    Read more at newswise.com
  • Louis V. Gerstner, Jr. to Conclude 8 Year Term as Chair of Broad Institute Board

    The Broad Institute of MIT and Harvard announced today that renowned technologist, entrepreneur and philanthropist Eric Schmidt will become the next Chair of the Board of Directors, succeeding Louis V. Gerstner, Jr., who has served as Chair of the Board since 2013. Under his leadership as Chair, the Broad Institute has expanded its focus and impact around mental illness, genome editing, cancer diagnostics, therapeutics and drug discovery, developing software tools to drive the intersection of biology and machine learning, COVID-19 testing and research to serve public health needs, and more.

    Read more at broadinstitute.org